(Q59801804)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

title

Vandetanib (ZD6474) induces antiangiogenesis through mTOR-HIF-1 alpha-VEGF signaling axis in breast cancer cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

author name string

Ling Li

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Jingkui Yu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Shuhong Jiao

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Wei Wang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Fen Zhang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Shiqing Sun

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

language of work or name

English

0 references

publication date

29 November 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

published in

OncoTargets and Therapy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

page(s)

8543-8553

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial 3.0 Unported

14 April 2020

copyright license

start time

1 November 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

describes a project that uses

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6278704/fullTextXML

inferred from PubMed Central ID database lookup

cites work

Dauricine inhibits insulin-like growth factor-I-induced hypoxia inducible factor 1alpha protein accumulation and vascular endothelial growth factor expression in human breast cancer cells

1 reference

12 December 2020

Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells

1 reference

12 December 2020

Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.

1 reference

12 December 2020

Vandetanib therapy in medullary thyroid cancer

1 reference

12 December 2020

Ascofuranone suppresses EGF-induced HIF-1α protein synthesis by inhibition of the Akt/mTOR/p70S6K pathway in MDA-MB-231 breast cancer cells

1 reference

12 December 2020

The discovery and development of vandetanib for the treatment of thyroid cancer

1 reference

12 December 2020

The quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro and in vivo by targeting the hypoxia inducible factor-1 pathway

1 reference

12 December 2020

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.

1 reference

12 December 2020

Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway

1 reference

12 December 2020

Andrographolide inhibits hypoxia-inducible factor-1 through phosphatidylinositol 3-kinase/AKT pathway and suppresses breast cancer growth

1 reference

12 December 2020

The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells

1 reference

12 December 2020

Paeoniflorin prevents hypoxia-induced epithelial-mesenchymal transition in human breast cancer cells

1 reference

12 December 2020

MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1α/VEGF signaling axis in breast cancer cells

1 reference

12 December 2020

CNOT2 promotes proliferation and angiogenesis via VEGF signaling in MDA-MB-231 breast cancer cells.

1 reference

12 December 2020

Centchroman regulates breast cancer angiogenesis via inhibition of HIF-1α/VEGFR2 signalling axis.

1 reference

12 December 2020

VEGF-induced intracellular Ca2+ oscillations are down-regulated and do not stimulate angiogenesis in breast cancer-derived endothelial colony forming cells

1 reference

12 December 2020

The hypoxia-responsive long non-coding RNAs may impact on the tumor biology and subsequent management of breast cancer.

1 reference

12 December 2020

In Situ shRNA Synthesis on DNA-Polylactide Nanoparticles to Treat Multidrug Resistant Breast Cancer.

1 reference

12 December 2020

Hypoxia induces miR-153 through the IRE1α-XBP1 pathway to fine tune the HIF1α/VEGFA axis in breast cancer angiogenesis.

1 reference

12 December 2020

Opposite response to hypoxia by breast cancer cells between cell proliferation and cell migration: A clue from microRNA expression profile.

1 reference

12 December 2020

Essential role of Polo-like kinase 1 (Plk1) oncogene in tumor growth and metastasis of tamoxifen-resistant breast cancer.

1 reference

12 December 2020

Angiogenesis - a crucial step in breast cancer growth, progression and dissemination by Raman imaging

1 reference

12 December 2020

A usable model of "decathlon winner" cancer cells in triple-negative breast cancer: survival of resistant cancer cells in quiescence.

1 reference

12 December 2020

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results

1 reference

12 December 2020

A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity.

1 reference

12 December 2020

Identifiers

DOI

10.2147/OTT.S175578

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

PubMed publication ID

30555244

1 reference